The invention provides an antibody or antigen binding fragments thereof that binds to 3pE A and methods of making and using the antibody or antigen binding fragment thereof, including use for formulations, administration and kits. The antibody and antigen binding fragments thereof and methods disclosed are useful for diagnosis, prognosis and treatment of Alzheimer's disease or other -amyloid-related diseases.

The invention provides an antibody or antigen binding fragments thereof that binds to 3pE A and methods of making and using the antibody or antigen binding fragment thereof, including use for formulations, administration and kits. The antibody and antigen binding fragments thereof and methods disclosed are useful for diagnosis, prognosis and treatment of Alzheimer's disease or other -amyloid-related diseases.

The invention provides an antibody or antigen binding fragments thereof that binds to 3pE A and methods of making and using the antibody or antigen binding fragment thereof, including use for formulations, administration and kits. The antibody and antigen binding fragments thereof and methods disclosed are useful for diagnosis, prognosis and treatment of Alzheimer's disease or other -amyloid-related diseases.

Nanoparticle-based nanosensors comprising supramolecular recognition sequences, protease consensus sequences, post-translationally modifiable sequences, or sterically hindered benzylether bonds for specific interaction with a biological marker, and methods for rapid diagnosis of lung conditions using specified panels of target biomarkers.

The present specification discloses a retargeted endopeptidase pharmaceutical wherein the activity has been determined by the methods disclosed.

The present specification discloses a retargeted endopeptidase pharmaceutical wherein the activity has been determined by the methods disclosed.

In some aspects, the disclosure provides compositions and methods for detecting and monitoring the activity of pro teases in vivo using affinity assays. The disclosure relates, in part, to the discovery that biomarker nanoparticles targeted to the lymph nodes of a subject are useful for the diagnosis and monitoring of certain medical conditions (e.g., metastatic cancer, infection with certain pathogenic agents).

We disclose a method of detecting the metabolic health of a mammal, including a human, by determining whether a given animal is normal, pre-diabetic or diabetic through the determination of the levels of Wnt4 and Wnt3a proteins in the blood serum.

A method of isolating barrel-like proteases is disclosed. The method comprising isolating barrel-like proteases from a biological sample containing the barrel-like proteases under conditions that maintain the content of the barrel-like protease-processed peptides in the barrel-like proteases upon isolation. A method of isolating barrel-like protease-processed peptides and a method of identifying barrel-like protease-processed peptides are also disclosed.

The present specification discloses a retargeted endopeptidase pharmaceutical wherein the activity has been determined by the methods disclosed.